News and Trends 23 Jul 2018
Sangamo Acquires French Biotech to Develop CAR-T Therapies for Autoimmune Disease
Sangamo Therapeutics has acquired TxCell with a view to utilizing its CAR-T technology to prevent organ transplant rejections and treat autoimmune disease. Sangamo, based in California, is known for bringing the first in-vivo gene therapy to the market. The company entered into an agreement to purchase TxCell for €72M. Sangamo plans to combine its zinc […]